Join the live Q&A on PrEP, the latest in HIV prevention. Text your questions to 713-526-1111 and tune in Monday to learn ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

If approved, lenacapavir has the potential to revolutionise HIV preexposure prophylaxis (PrEP). Gilead’s lenacapavir, an HIV-1 capsid inhibitor, is already marketed in the US, EU, and numerous ...

Preexposure prophylaxis (PrEP) is a medication that helps prevent the contraction of HIV. People with a high risk of HIV exposure may choose to take PrEP. It is safe for transgender people.

The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...